AxoGen, Inc. reports results for the quarter ended September 30 - Earnings Summary

What happened

AxoGen, Inc. reported quarterly adjusted earnings of 21 cents per share, above the 12 cents reported a year earlier and the 14 cents expected by eleven analysts. Revenue rose 26.2% to $75.83 million, beating the $73.20 million analysts expected, while reported earnings per share were 4 cents.

Confirmed

Global impact / market context

The earnings beat means AxoGen earned more profit per sale than Wall Street expected, which can support the case for future capital spending on growth. Higher revenue also gives the company more cash available to fund operations without relying as heavily on borrowed money.

Analyst inference

Despite the results, AxoGen shares had fallen 10.6% this quarter while gaining 14.5% so far this year, suggesting investors weighed other concerns. The average analyst rating is buy, with a median 12-month price target of $53.00, about 29.3% above the last closing price of $37.46.

Analyst inference

What to watch

1. Analysts' mean earnings estimate rose about 1.5% in the last three months, and there were no negative revisions in the last 30 days, which means forecasters have not recently cut their profit expectations for the company. Confirmed
2. Watch whether AxoGen can keep revenue growing fast enough to justify higher capital spending and protect profit per sale, since the article supplies no company guidance or spending plans for coming quarters. Proposed
3. Watch the gap between the $37.46 last closing price and the $53.00 median price target, because it shows investors may be pricing in risks that the earnings beat alone has not resolved. Analyst inference

Evidence

• Original source link unavailable